VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease (1)
DOSAGE AND ADMINISTRATION

• Recommended Starting Dose in Adults and Pediatric Patients 4 Years of Age or Older:
  • Patients Naïve to Enzyme Replacement Therapy: 60 Units/kg (2.1)
  • Patients being treated with stable imiglucerase dosages for Gaucher disease: Can switch to VPRIV at previous imiglucerase dose two weeks after last imiglucerase dose (2.2).
• Determine number of vials to be reconstituted based on patient's actual weight and prescribed dose (2.3)
• Supplied VPRIV lyophilized powder must be reconstituted with Sterile Water for Injection (2.3)
• Reconstituted VPRIV solution must be diluted in 100 mL of 0.9% sodium chloride solution prior to intravenous infusion (2.3)
• Administer the diluted VPRIV solution through an in-line low protein-binding 0.2μm filter (2.4)

None (4)
WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis:

• Hypersensitivity reactions including anaphylaxis have occurred.(5.1)
• Ensure that personnel administering product are adequately trained in cardiopulmonary resuscitative measures, and have ready access to emergency medical services (5.1)
• Consider slowing infusion rate, treatment with antihistamines, antipyretics and/or corticosteroids, and/or stopping treatment if a hypersensitivity reaction occurs during an infusion. Consider pre-treatment with antihistamines and/or corticosteroids in patients with prior reactions (